Advertisement Pharmaceutical Business review - Page 570 of 5223 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 25, 2024

Lyell signs agreement to acquire ImmPACT Bio

Lyell Immunopharma has entered into a definitive agreement for the acquisition of ImmPACT Bio USA, a move that is expected to prioritise its pipeline to focus on chimeric antigen receptor (CAR) T-cell therapies.

Continue
In line with the acquisition, Lyell has prioritised its pipeline, focusing on its most differentiated CAR T-cell clinical programmes. Credit: Lucas Vasques on Unsplash.
October 24, 2024

FDA issues CRL to PharmaTher’s ketamine ANDA

The FDA's CRL requested new and updated information along with clarifications on the drug substance. Credit: freestocks on Unsplash.
October 23, 2024

TerSera acquires global rights to MacroGenics’ MARGENZA for breast cancer treatment

MacroGenics is into the discovery, development, manufacturing, and commercialization of monoclonal antibody-based therapies for cancer treatment. Credit: AVAKA photo from Pixabay.

Contracts

August 9, 2024

Bavarian Nordic secures $156.8m US vaccine deal

The vaccine is marketed under various brand names. Credit: Mathurin NAPOLY / matnapo on Unsplash.

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Deals

Deals July 15, 2024

Merck enhances ophthalmology portfolio with EyeBio acquisition

Pharmaceutical Business Review

Biocon signs licensing and supply deal for diabetes drug in Brazil

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Popular

  1. Samsung Biologics signs $1.24bn manufacturing deal with Asian pharma company
  2. Novartis gets positive CHMP opinion for Kisqali in early breast cancer
  3. AscellaHealth acquires specialty pharmaceutical wholesaler CHAPPER healthcare
  4. Astria Therapeutics’ navenibart gains orphan medicinal status from EC
  5. RTI partners with Codetta Bio to boost healthcare innovation

PRESS RELEASES

Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer: EcoVadis Gold with Further Improved Score
Gerresheimer: EcoVadis Gold with Further Improved Score
Gerresheimer: Innovative Silicone Oil-Free Syringe Systems for Sensitive Ophthalmic Drugs
Gerresheimer: Innovative Silicone Oil-Free Syringe Systems for Sensitive Ophthalmic Drugs
Gerresheimer Remains on Track in First Half of 2024
Gerresheimer Remains on Track in First Half of 2024
RWS Joins Meta’s Open Loop Programme to Shape Future of AI Policy
RWS Joins Meta’s Open Loop Programme to Shape Future of AI Policy

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation